Barcelona’s Ona takes aim at metastasis with €30M series A

A European investor syndicate has funded Ona with €30 million ($33.8 million) to develop an antibody program targeting a lipid metabolism pathway whose inhibition has been associated with prevention of metastasis.

Barcelona-based Asabys Partners, which was Ona Therapeutics’ seed investor, participated in the round alongside new investors Alta Life Sciences, Bpifrance’s InnoBio 2, Fund+ and Ysios Capital...